产后出血管理集束化方案实施后血液制品输注的患病率:单中心安全网学术机构的回顾性队列研究
该回顾性队列研究在单中心安全网教学医院比较了2017年10月至2019年12月(排除2018年9月至12月推广期)产后出血集束化方案实施前后血液制品输注的患病率。共纳入6744例分娩,方案实施前后任何血液制品输注率相似(3.41% vs 3.47%,P=.892),但产后出血患病率升高(7.05% vs 10.34%,P<.001),产后出血患者中输血率降低(36.05% vs 26.84%,P=.018),宫内球囊使用率升高(10.30% vs 16.95%,P=.024)。
要点
- 集束化方案实施前后总体血液制品输注率无显著差异(3.41% vs 3.47%,P=.892)。
- 产后出血患者中,方案实施后输血率低于实施前(26.84% vs 36.05%,P=.018)。
- 产后出血患者中,方案实施后宫内球囊放置率高于实施前(16.95% vs 10.30%,P=.024)。
核心结论
- 产后出血集束化方案的实施未降低总体血液制品输注患病率,并可能导致资源使用率升高。
研究设计与样本
- 单中心安全网教学医院的回顾性队列研究,比较集束化方案实施前后血液制品输注患病率。
- 纳入2017年10月至2019年12月期间分娩、年龄≥18岁且孕周>20周的患者,排除院外分娩、显著非产科创伤时分娩及拒绝输血者。
- 排除2018年9月至2018年12月共4个月的推广期。
- 共纳入6744例分娩,实施前队列3310例,实施后队列3425例。
主要发现
- 任何血液制品输注患病率在实施前队列为3.41%(113/3310),实施后队列为3.47%(119/3425),差异无统计学意义(P=.892)。
- 产后出血患病率在实施前队列为7.05%(233/3310),实施后队列为10.34%(354/3434),差异有统计学意义(P<.001)。
- 产后出血患者中,实施前队列输血率为36.05%(84/233),实施后队列为26.84%(95/354),差异有统计学意义(P=.018)。
- 产后出血患者中,实施后队列宫内球囊放置率高于实施前队列(16.95%;60/354 vs 10.30%;24/233;P=.024)。
- 其他次要结局无显著差异;失血量≥1000 mL者总体集束化方案依从性为92.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum hemorrhage, defined as blood loss of ≥1000 mL within 24 hours after birth, is a leading cause of maternal morbidity and is associated with substantial financial and emotional burden. Based on societal and regulatory guidelines, in 2019, our institution adopted a postpartum hemorrhage prevention and management bundle based on the California Maternal Quality Care Collaborative initiatives. OBJECTIVE: The study aimed to compare the prevalence of maternal blood product transfusion before and after the implementation of the bundle. STUDY DESIGN: This was a retrospective cohort study comparing the prevalence of blood product transfusion before and after the implementation of a California Maternal Quality Care Collaborative-based postpartum hemorrhage management bundle at a single safety net teaching hospital between October 2017 and December 2019 excluding a 4-month rollout period between September 2018 and December 2018. The study included all patients ≥18 years of age and at >20 weeks' gestation. Exclusion criteria were out-born deliveries, delivery at time of significant nonobstetrical trauma, and refusal of blood transfusion. The primary outcome was the frequency of any blood product transfusion in the pre- and postbundle implementation cohorts. Secondary outcomes included blood product transfusion type and amount, maternal death, intrauterine balloon placement, uterine artery embolization, unplanned peripartum hysterectomy, intensive care admission, and length of stay among all deliveries complicated by postpartum hemorrhage. We further evaluated compliance with bundle measures for all postpartum hemorrhage cases. Cohort characteristics were compared using chi-square tests or Fisher exact tests for categorical data and Satterthwaite or Wilcoxon 2-sample tests for continuous variables based on data distributions. The proportion of blood product transfusion were evaluated using a chi-square test. RESULTS: A total of 6744 deliveries were included with 3310 in the pre- and 3425 in the postbundle cohort. The prevalence of any blood product transfusion was similar between the pre- and postbundle cohorts (3.41%; 113/3310 vs 3.47%; 119/3425; P=.892). The prevalence of postpartum hemorrhage was 7.05% (233/3310) in the prebundle cohort and 10.34% (354/3434) in the postbundle cohort (P<.001). Among women with postpartum hemorrhage, those in the prebundle cohort had a higher rate of blood product transfusion than those in the postbundle cohort (36.05%; 84/233 vs 26.84%; 95/354; P=.018). Compared with the prebundle counterparts, patients with postpartum hemorrhage in the postbundle cohort had higher rates of utilization of intrauterine balloon placement (10.30%; 24/233 vs 16.95%; 60/354; P=.024). There were no significant differences among other secondary outcomes. The overall compliance with the bundle among those with blood loss ≥1000 mL was 92.1%. CONCLUSION: The implementation of the postpartum hemorrhage bundle did not decrease the overall prevalence of blood product transfusion and may have led to higher rates of utilization of resources.
引用
- Sullivan J, Rockhill K, Larrea N, et al. The prevalence of blood product transfusion after the implementation of a postpartum hemorrhage bundle: a retrospective cohort at a single safety net academic institution. Am J Obstet Gynecol MFM. 2022. PMID: 35577315. doi:10.1016/j.ajogmf.2022.100662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。